The estimated Net Worth of Mark Stenhouse is at least $8.21 Milion dollars as of 2 April 2020. Mr. Stenhouse owns over 25,000 units of Exact Sciences stock worth over $2,662,198 and over the last 6 years he sold EXAS stock worth over $0. In addition, he makes $5,545,050 as General Manager - Screening at Exact Sciences.
Mark has made over 3 trades of the Exact Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of EXAS stock worth $1,603,000 on 2 April 2020.
The largest trade he's ever made was exercising 25,000 units of Exact Sciences stock on 2 April 2020 worth over $1,603,000. On average, Mark trades about 4,842 units every 33 days since 2018. As of 2 April 2020 he still owns at least 41,519 units of Exact Sciences stock.
You can see the complete history of Mr. Stenhouse stock trades at the bottom of the page.
Mark Stenhouse serves as General Manager - Screening of the Company. Mr. Stenhouse has served as President, Cologuard since April 2018. Prior to joining Exact, Mr. Stenhouse worked for over 25 years at Abbott Laboratories (NYSE: ABT) and AbbVie, Inc. (NYSE: ABVV), including in a number of executive and managerial positions within its U.S. Immunology division. Most recently, from October 2016 until March 2018, Mr. Stenhouse served as Vice President, U.S. Immunology, where Mr. Stenhouse developed AbbVie's U.S. expansion into the immunology marketplace. From April 2010 until September 2016, Mr. Stenhouse served as Vice President and Vice President/General Manager, U.S. Immunology—Gastroenterology Franchise, where Mr. Stenhouse led a successful turnaround of the franchise, including approval of HUMIRA for treatment of Ulcerative Colitis. From September 2006 through March 2010, Mr. Stenhouse held various senior management, marketing and sales positions within Abbott Laboratories' U.S. Immunology division. Mr. Stenhouse earned a bachelor's degree in business administration from College of Charleston.
As the General Manager - Screening of Exact Sciences, the total compensation of Mark Stenhouse at Exact Sciences is $5,545,050. There are 1 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.
Mark Stenhouse is 53, he's been the General Manager - Screening of Exact Sciences since 2019. There are 17 older and 6 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PAK, NJ, 07932.
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania oraz Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Exact Sciences executives and other stock owners filed with the SEC include: